Table 3 Cell cycle pathway alterations found in study patients by IHC and next-generation sequencing
IDa | RB IHC | p16 IHC | Gene | Alteration | Predicted sensitivity to palbociclib | PFS4 |
|---|---|---|---|---|---|---|
1 | 3+ in 20% 2+ in 40% 1+ in 30% 0+ in 10% | 3+ staining in 30% | CDKN1A CDKN1A | Asp28Gly Pro4Leu | Resistant Resistant | No |
2 | 3+ in 10% 2+ in 20% 1+ in 20% 0+ in 50% | No staining | CDKN2B | Shallow deletion | Sensitive | No |
3 | 3+ in 30% 2+ in 40% 1+ in 30% | No staining | Nonea | No | ||
4 | 2+ in 30% 1+ in 40% 0+ in 30% | No staining | CDKN2B | Shallow deletion | Sensitive | No |
5 | 2+ in 70% 1+ in 20% 0+ in 10% | No staining | CDKN2B | Deep deletion | Sensitive | No |
6 | 2+ in 10% 1+ in 80% 0+ in 10% | No staining | Nonea | No | ||
7 | 3+ in 30% 2+ in 40% 1+ in 30% | No staining | E2F3 | Gain | Resistant | No |
8 | 2+ in 30% 1+ in 70% | No staining | CCNE1 CDKN1A CDKN1A | Gain Asp28Gly Pro4Leu | Resistant Resistant Resistant | Yes |
9 | 2+ in 30% 1+ in 60% 0+ in 10% | 1 + staining in 90% | RB1 | Amplification | N/A | No |
10 | 2+ in 50% 1+ in 30% 0+ in 20% | No staining | CDKN1A | FS111 | Resistant | Yes |
11 | 3+ in 20% 2+ in 20% 1+ in 10% | No staining | E2F3 | Asp389Asn | Resistant | No |
12 | 3+ in 10% 2+ in 30% 1+ in 30% 0+ in 30% | No staining | Unknowna | No |
